29 reports

start=###content (Accessed: ## August 2017).

  • Pancreatic Cancer
  • Japan
  • United States
  • World
  • Forecast

CURRENTLY, IMBRUVICA IS MARKETED FOR MULTIPLE INDICATIONS INCLUDING MANTLE CELL LYMPHOMA (MCL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/ SMALL LYMPHOCYTIC LEUKEMIA (SLL), WALDENSTROM' S MACROGLOBULINEMIA (WM), MARGINAL ZONE LYMPHOMA (MZL), AND CHRONIC GRAFT VERSUS HOST DISEASE (

  • Pancreatic Cancer
  • AbbVie Inc.
  • AstraZeneca PLC
  • Halozyme Therapeutics, Inc.
  • Merck & Co., Inc.

MGH is # ## in the Nation.

  • Artificial Intelligence
  • Hospital
  • Pancreatic Cancer
  • United States
  • GE Healthcare Limited
  • Number of Products under Development by Indications, H2 2018
  • Products under Development by Companies, H2 2018

The molecules developed by companies in Phase II, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Pancreatic Cancer
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • Erytech Pharma Raises USD38 Million in Private Placement of Shares

Each ADS represents the right to receive one ordinary share.

  • Pancreatic Cancer
  • Pharmaceutical
  • Europe
  • United States
  • Erytech Pharma SA
  • PIPELINE BY ONCOVIR INC, H1 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018

The molecules developed by companies in Filing rejected/ Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Pancreatic Cancer
  • Pharmaceutical
  • Therapy
  • Vaccine
  • Hemispherx Biopharma, Inc.

Each ADS represents the right to receive one ordinary share.

  • Pancreatic Cancer
  • United States
  • Company
  • Product Initiative
  • Erytech Pharma SA

FIGURE ##.

  • Pancreatic Cancer
  • World
  • Forecast
  • Market Size
  • PharmaCyte Biotech, Inc.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Medical Biotechnology
  • Monoclonal Antibody
  • Pancreatic Cancer
  • Therapy
  • Etubics Corporation
  • Clinical Trial profile. 501 Trial Title
  • Clinical Trial profile. 142 Trial Title

The prominent features of this report are - ##.

  • Clinical Trial
  • Hepatitis
  • Pancreatic Cancer
  • Therapy
  • World

Korfin oversaw the market access strategy, including payer relations and reimbursement, for Yescarta, the first approved CAR-T therapy in lymphoma.

  • Pancreatic Cancer
  • Pharmaceutical
  • United States
  • Company
  • Tyme Technologies, Inc
  • DORMANT PRODUCTS, H1 2019 (CONTD..4), H1 2019
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2019

In addition, MDX-## also reduced tumor growth in acute myelogenous leukemia and lymphoma xenograft models.

  • Lung Cancer
  • Pancreatic Cancer
  • United States
  • Product Initiative
  • BioLineRx Ltd.

NCCN Guidelines: B-Cell Lymphomas.

  • Breast Cancer
  • Epidemiology
  • Pancreatic Cancer
  • Therapy
  • Product Initiative
  • TRA-8
  • PANCREATIC CANCER - PIPELINE BY BEIGENE LTD

Verastem' s VS. -## and VS. -## is used for the treatment of solid tumors and lymphomas.

  • Cancer
  • Pancreatic Cancer
  • Pharmaceutical
  • Therapy
  • Product Initiative

IN ADDITION, MDX-## ALSO REDUCED TUMOR GROWTH IN ACUTE MYELOGENOUS LEUKEMIA AND LYMPHOMA XENOGRAFT MODELS.

  • Pancreatic Cancer
  • Renal Cancer
  • United States
  • Product Initiative
  • BioLineRx Ltd.
  • IMMUNOVIA ENTERS INTO AGREEMENT WITH UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER

" The important prospective studies for the pancreas test within the diabetes group (" PANDIA-##) and the early symptoms group (" PANSYM-##) have in discussions with clinical partners made progress for both PANDIA-## and PANSYM-##.

  • Autoimmune Disease
  • Cancer
  • Pancreatic Cancer
  • Sweden
  • United States
  • DIAGNOSTIC TEST - PANCREATIC CANCER - PRODUCT DESCRIPTION
  • FRED HUTCHINSON CANCER RESEARCH CENTER PIPELINE PRODUCTS & ONGOING CLINICAL TRIALS OVERVIEW

FOOD AND DRUG ADMINISTRATION VOTED ## TO ## THAT THE BENEFIT/ RISK OF RITUXIMAB/ HYALURONIDASE FOR SUBCUTANEOUS INJECTION WAS FAVORABLE FOR PATIENTS IN THE PROPOSED INDICATIONS OF FOLLICULAR LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA.

  • Biomarker
  • Cancer
  • Clinical Trial
  • Pancreatic Cancer
  • Proteome Sciences
  • PARTNERSHIPS

" The important prospective studies for the pancreas test within the diabetes group (" PANDIA-##) and the early symptoms group (" PANSYM-##) have in discussions with clinical partners made progress for both PANDIA-## and PANSYM-##.

  • Healthcare
  • Pancreatic Cancer
  • Pharmaceutical
  • Sweden
  • United States

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Development
  • Pancreatic Cancer
  • World
  • Eli Lilly & Co.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2016
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2016

CEP-## is a dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with antineoplastic activity.

  • Medical Biotechnology
  • Pancreatic Cancer
  • United States
  • Product Initiative
  • Verastem, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2016

It is in Phase II stage of development for advanced carcinoid and pancreatic neuroendocrine tumors and various advanced solid tumor types, metastatic colorectal cancer and lymphomas.

  • Insulin
  • Lung Cancer
  • Pancreatic Cancer
  • United States
  • Product Initiative
  • METASTATIC PANCREATIC CANCER - PIPELINE BY PHARMACYCLICS, INC., H1 2016
  • Metastatic Pancreatic Cancer - Recent Pipeline Updates

Two relapsed lymphoma patients, one with Burkitt' s lymphoma and a second with cutaneous T-cell lymphoma, achieved prolonged partial responses in this study.

  • Chemotherapy
  • Pancreatic Cancer
  • United States
  • Company
  • Product Initiative
  • ACALABRUTINIB - DRUG PROFILE
  • METASTATIC PANCREATIC CANCER - PIPELINE BY PHARMACYCLICS, INC., H2 2016

Two relapsed lymphoma patients, one with Burkitt' s lymphoma and a second with cutaneous T-cell lymphoma, achieved prolonged partial responses in this study.

  • Cancer
  • Pancreatic Cancer
  • United States
  • Company
  • Product Initiative
  • PIPELINE BY BRISTOL-MYERS SQUIBB COMPANY, H2 2016
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2016 (CONTD..1)

IN ADDITION, MDX-## ALSO REDUCED TUMOR GROWTH IN ACUTE MYELOGENOUS LEUKEMIA AND LYMPHOMA XENOGRAFT MODELS.

  • Oncology
  • Pancreatic Cancer
  • Research And Development
  • Therapy
  • BioLineRx Ltd.

Insulin-like growth factor-## (IGF-##) is administered through subcutaneous route.

  • Hospital
  • Insulin
  • Pancreatic Cancer
  • Pharmaceutical
  • Therapy
  • Number of Products under Development by Indication, H1 2016
  • Products under Development by Companies, H1 2016

SST## is the front runner product within this unique platform and has proven efficacious in several preclinical models of hematologic malignancies (MM and lymphomas) and of certain solid tumors as sarcoma or bone metastasis.

  • Pancreatic Cancer
  • Pharmaceutical
  • United States
  • Product Initiative
  • Progen Pharmaceuticals Limited

The company also concentrates on cancer, multiple myeloma (MM) and other B-cell cancers including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL).

  • Pancreatic Cancer
  • Therapy
  • United States
  • Product Initiative
  • OncoMed Pharmaceuticals, Inc.

The Phase II " DENALI" trial is expected to enroll approximately ## patients with first-line metastatic Stage IV non-squamous NSCLC whose tumors do not have an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation.

  • Medical Biotechnology
  • Pancreatic Cancer
  • Pharmaceutical
  • Company Operations
  • OncoMed Pharmaceuticals, Inc.

The Cmax and AUC values on cycle ## day ## increased in an almost dose-proportional manner within a dose range of ## to ## mg/ m##.

  • Medical Biotechnology
  • Monoclonal Antibody
  • Pancreatic Cancer
  • Therapy
  • Morphotek, Inc.